

Michael S Hofman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1735518/publications.pdf>

Version: 2024-02-01

256
papers

13,862
citations

30070

54
h-index

24258

110
g-index

258
all docs

258
docs citations

258
times ranked

9686
citing authors

#	ARTICLE	IF	CITATIONS
1	Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. <i>Lancet, The</i> , 2020, 395, 1208-1216.	13.7	1,108
2	[¹⁷⁷ Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2018, 19, 825-833.	10.7	823
3	Sensitivity, Specificity, and Predictors of Positive ⁶⁸ Ga-PSMA PET/CT in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2016, 70, 926-937.	1.9	819
4	Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2020, 77, 403-417.	1.9	614
5	[¹⁷⁷ Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. <i>Lancet, The</i> , 2021, 397, 797-804.	13.7	552
6	Somatostatin Receptor Imaging with ⁶⁸ Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation. <i>Radiographics</i> , 2015, 35, 500-516.	3.3	435
7	¹⁸ F-fluciclovine PET-CT and ⁶⁸ Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. <i>Lancet Oncology, The</i> , 2019, 20, 1286-1294.	10.7	338
8	Dosimetry of ¹⁷⁷ Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. <i>Journal of Nuclear Medicine</i> , 2019, 60, 517-523.	5.0	285
9	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	1.9	278
10	International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers. <i>Journal of Nuclear Medicine</i> , 2013, 54, 683-690.	5.0	267
11	Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. <i>Radiographics</i> , 2018, 38, 200-217.	3.3	262
12	Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial. <i>European Urology</i> , 2018, 74, 455-462.	1.9	250
13	The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale. <i>Haematologica</i> , 2014, 99, 1107-1113.	3.5	225
14	High management impact of ⁶⁸ Ga DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2012, 56, 40-47.	1.8	217
15	Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷ Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 857-865.	5.0	191
16	Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7448-7454.	7.0	190
17	E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1626-1638.	6.4	188
18	The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. <i>European Urology</i> , 2021, 80, 682-689.	1.9	181

#	ARTICLE	IF	CITATIONS
19	Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. <i>Journal of Nuclear Medicine</i> , 2017, 58, 67S-76S.	5.0	163
20	Is there still a role for SPECT-CT in oncology in the PET-CT era?. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 712-720.	27.6	135
21	⁶⁸ Ga-DOTATATE and ¹⁸ F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity. <i>Cancer Imaging</i> , 2016, 16, 22.	2.8	135
22	Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for ¹⁷⁷ Lu-labelled PSMA Radioligand Therapy. <i>European Urology Oncology</i> , 2019, 2, 670-676.	5.4	134
23	Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3278-3287.	3.6	125
24	Nomograms to predict outcomes after ¹⁷⁷ Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. <i>Lancet Oncology</i> , The, 2021, 22, 1115-1125.	10.7	120
25	The tumour sink effect on the biodistribution of ⁶⁸ Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 50-56.	6.4	119
26	The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 67-77.	6.4	112
27	Quantitative ¹⁷⁷ Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system. <i>Cancer Imaging</i> , 2011, 11, 56-66.	2.8	111
28	TheraP: a randomized phase 2 trial of ¹⁷⁷ Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol) https://doi.org/10.1186/s12916-019-1310-1	11.5	110
29	Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 87-96.	0.6	102
30	Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [¹⁷⁷ Lu]-PSMA-617. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2322-2327.	6.4	101
31	Improving Diagnosis of Tumor-Induced Osteomalacia With Gallium-68 DOTATATE PET/CT. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 687-694.	3.6	100
32	⁶⁴ Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 777-785.	5.0	98
33	Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 262-277.	6.4	97
34	A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol. <i>BJU International</i> , 2018, 122, 783-793.	2.5	96
35	Guidelines on nuclear medicine imaging in neuroblastoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2009-2024.	6.4	94
36	Favourable outcomes of ¹⁷⁷ Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 176-185.	6.4	91

#	ARTICLE	IF	CITATIONS
37	Development of standardized image interpretation for ⁶⁸ Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1622-1635.	6.4	91
38	⁶⁸ Ga PET/CT Ventilation-Perfusion Imaging for Pulmonary Embolism: A Pilot Study with Comparison to Conventional Scintigraphy. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1513-1519.	5.0	87
39	Deep Learning Renal Segmentation for Fully Automated Radiation Dose Estimation in Unsealed Source Therapy. <i>Frontiers in Oncology</i> , 2018, 8, 215.	2.8	85
40	High-resolution pulmonary ventilation and perfusion PET/CT allows for functionally adapted intensity modulated radiotherapy in lung cancer. <i>Radiotherapy and Oncology</i> , 2015, 115, 157-162.	0.6	83
41	Utility of ⁶⁸ Ga prostate specific membrane antigen positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2017, 61, 372-378.	1.8	83
42	Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 2072-2082.	6.4	81
43	How We Read Oncologic FDG PET/CT. <i>Cancer Imaging</i> , 2016, 16, 35.	2.8	81
44	Validating and improving CT ventilation imaging by correlating with ventilation 4D-PET/CT using ⁶⁸ Ga-labeled nanoparticles. <i>Medical Physics</i> , 2013, 41, 011910.	3.0	79
45	Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1831-1844.	6.4	79
46	Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol. <i>Thyroid</i> , 2019, 29, 1634-1645.	4.5	69
47	Detection and localisation of primary prostate cancer using ⁶⁸ gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. <i>BJU International</i> , 2020, 126, 83-90.	2.5	69
48	Radiation Dosimetry in ¹⁷⁷ Lu-PSMA-617 Therapy Using a Single Posttreatment SPECT/CT Scan: A Novel Methodology to Generate Time- and Tissue-Specific Dose Factors. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1030-1036.	5.0	68
49	An automated voxelized dosimetry tool for radionuclide therapy based on serial quantitative SPECT/CT imaging. <i>Medical Physics</i> , 2013, 40, 112503.	3.0	66
50	The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable. <i>European Journal of Surgical Oncology</i> , 2012, 38, 64-71.	1.0	65
51	Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. <i>British Journal of Cancer</i> , 2013, 109, 312-317.	6.4	64
52	Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of ⁶⁸ Ga-Tris(Hydroxypyridinone)-PSMA PET/CT in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 625-631.	5.0	62
53	Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 2971-2980.	1.6	61
54	Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. <i>Journal of Nuclear Medicine</i> , 2022, 63, 59-68.	5.0	61

#	ARTICLE	IF	CITATIONS
55	Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: Establishing a doseâ€“response relationship. <i>Radiotherapy and Oncology</i> , 2016, 118, 540-546.	0.6	60
56	The VAMPIRE challenge: A multiâ€“institutional validation study of CT ventilation imaging. <i>Medical Physics</i> , 2019, 46, 1198-1217.	3.0	59
57	Changing paradigms with molecular imaging of neuroendocrine tumors. <i>Discovery Medicine</i> , 2012, 14, 71-81.	0.5	59
58	TheraP: A randomised phase II trial of ¹⁷⁷ Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: Initial results (ANZUP protocol 1603).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5500-5500.	1.6	58
59	Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution. <i>Cancer Imaging</i> , 2019, 19, 23.	2.8	55
60	Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14. <i>Haematologica</i> , 2017, 102, 356-363.	3.5	53
61	Functional lung imaging in radiation therapy for lung cancer: A systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2018, 129, 196-208.	0.6	53
62	Is Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Cost-effective in Prostate Cancer: An Analysis Informed by the proPSMA Trial. <i>European Urology</i> , 2021, 79, 413-418.	1.9	52
63	Protocol for the PRIMARY clinical trial, a prospective, multicentre, crossâ€“sectional study of the additive diagnostic value of galliumâ€“68 prostateâ€“specific membrane antigen positronâ€“emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. <i>BJU International</i> , 2020, 125, 515-524.	2.5	51
64	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	1.9	51
65	TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FSTRACK II. <i>BMC Cancer</i> , 2018, 18, 1030.	2.6	50
66	Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 38-52.	3.9	50
67	PET/CT Lung Ventilation and Perfusion Scanning using Galligas and Gallium-68-MAA. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 71-81.	4.6	47
68	Changes in biodistribution on 68Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression. <i>Cancer Imaging</i> , 2018, 18, 3.	2.8	45
69	TheraP: ¹⁷⁷ Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxelâ€“Overall survival after median follow-up of 3 years (ANZUP 1603).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5000-5000.	1.6	44
70	High-resolution imaging of pulmonary ventilation and perfusion with 68Ga-VQ respiratory gated (4-D) PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 343-349.	6.4	43
71	Estimating lung ventilation directly from 4D CT Hounsfield unit values. <i>Medical Physics</i> , 2015, 43, 33-43.	3.0	42
72	High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with ¹⁷⁷ Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 476-489.	6.4	42

#	ARTICLE	IF	CITATIONS
73	FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2776-2786.	6.4	42
74	Tumor Sink Effect in ⁶⁸ Ga-PSMA-11 PET: Myth or Reality?. <i>Journal of Nuclear Medicine</i> , 2022, 63, 226-232.	5.0	42
75	Ventilation/Perfusion Positron Emission Tomography-Based Assessment of Radiation Injury to Lung. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 408-417.	0.8	41
76	Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer. <i>Nature Reviews Urology</i> , 2020, 17, 107-118.	3.8	41
77	Observer Variation in Interpreting ¹⁸ F-FDG PET/CT Findings for Lymphoma Staging. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1594-1597.	5.0	40
78	Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit. <i>Melanoma Research</i> , 2008, 18, 56-60.	1.2	39
79	Prostate-specific membrane antigen theranostics. <i>Current Opinion in Urology</i> , 2018, 28, 197-204.	1.8	39
80	Efficacy and Safety of ¹⁷⁷ Lu-labeled Prostate-specific Membrane Antigen Radionuclide Treatment in Patients with Diffuse Bone Marrow Involvement: A Multicenter Retrospective Study. <i>European Urology</i> , 2020, 78, 148-154.	1.9	39
81	Detection of Synchronous Primary Malignancies with ⁶⁸ Ga-Labeled Prostate-Specific Membrane Antigen PET/CT in Patients with Prostate Cancer: Frequency in 764 Patients. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1938-1942.	5.0	38
82	Prostate-specific Membrane Antigen PET in Prostate Cancer. <i>Radiology</i> , 2021, 299, 248-260.	7.3	38
83	Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1902-1910.	6.4	37
84	PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics. <i>World Journal of Urology</i> , 2019, 37, 1255-1261.	2.2	37
85	[⁶⁸ Ga]Ga-PSMA Versus [¹⁸ F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2022, 5, 273-282.	5.4	37
86	Pulmonary Scintigraphy for the Diagnosis of Acute Pulmonary Embolism: A Survey of Current Practices in Australia, Canada, and France. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1212-1217.	5.0	36
87	⁶⁸ Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends. <i>Prostate International</i> , 2017, 5, 125-129.	2.3	36
88	¹⁸ F-FDG Avid Thyroid Incidentalomas: The Importance of Contextual Interpretation. <i>Journal of Nuclear Medicine</i> , 2018, 59, 749-755.	5.0	35
89	Ga-68 MAA Perfusion 4D-PET/CT Scanning Allows for Functional Lung Avoidance Using Conformal Radiation Therapy Planning. <i>Technology in Cancer Research and Treatment</i> , 2016, 15, 114-121.	1.9	33
90	UpFrontPSMA: a randomized phase 2 study of sequential ¹⁷⁷ Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol). <i>BJU International</i> , 2021, 128, 331-342.	2.5	33

#	ARTICLE	IF	CITATIONS
91	Rapid blood clearance and lack of long-term renal toxicity of ¹⁷⁷ Lu-DOTATATE enables shortening of renoprotective amino acid infusion. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1853-1860.	6.4	32
92	⁶⁸ Ga-EDTA PET/CT Imaging and Plasma Clearance for Glomerular Filtration Rate Quantification: Comparison to Conventional ⁵¹ Cr-EDTA. <i>Journal of Nuclear Medicine</i> , 2015, 56, 405-409.	5.0	32
93	The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET. <i>Breast Cancer Research</i> , 2010, 12, R37.	5.0	31
94	Distribution Atlas of Proliferating Bone Marrow in Non-Small Cell Lung Cancer Patients Measured by FLT-PET/CT Imaging, With Potential Applicability in Radiation Therapy Planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 1035-1043.	0.8	31
95	Does PET SUV Harmonization Affect PERCIST Response Classification?. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1699-1706.	5.0	31
96	Accuracy of Dose Calibrators for ⁶⁸ Ga PET Imaging: Unexpected Findings in a Multicenter Clinical Pretrial Assessment. <i>Journal of Nuclear Medicine</i> , 2018, 59, 636-638.	5.0	31
97	Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of ¹⁷⁷ Lu-PSMA-617 Prior to Prostatectomy. <i>European Urology Focus</i> , 2021, 7, 234-237.	3.1	31
98	Assessing response to chemotherapy in metastatic melanoma with FDG PET: Early experience. <i>Nuclear Medicine Communications</i> , 2007, 28, 902-906.	1.1	29
99	Correlation of ⁶⁸ Ga Ventilation-Perfusion PET/CT with Pulmonary Function Test Indices for Assessing Lung Function. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1718-1723.	5.0	29
100	Gallium-68 EDTA PET/CT for Renal Imaging. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 448-461.	4.6	29
101	Gallium-68 Prostate-Specific Membrane Antigen PET Imaging. <i>PET Clinics</i> , 2017, 12, 219-234.	3.0	29
102	Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart. <i>Journal of Clinical Oncology</i> , 2019, 37, 765-769.	1.6	29
103	Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET?. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987682.	3.2	28
104	Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 211-213.	6.4	27
105	Advances in Urologic Imaging. <i>Urologic Clinics of North America</i> , 2018, 45, 503-524.	1.8	27
106	Short communication: timeline of radiation-induced kidney function loss after stereotactic ablative body radiotherapy of renal cell carcinoma as evaluated by serial ^{99m} Tc-DMSA SPECT/CT. <i>Radiation Oncology</i> , 2014, 9, 253.	2.7	26
107	A prospective observational study of Gallium-68 ventilation and perfusion PET/CT during and after radiotherapy in patients with non-small cell lung cancer. <i>BMC Cancer</i> , 2014, 14, 740.	2.6	26
108	Moving Beyond "Lumpology": PET/CT Imaging of Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2015, 21, 3815-3817.	7.0	24

#	ARTICLE	IF	CITATIONS
109	The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5091-5099.	3.6	23
110	The role of ¹⁸ F-FDG PET/CT in retroperitoneal sarcomas: A multicenter retrospective study. <i>Journal of Surgical Oncology</i> , 2021, 123, 1081-1087.	1.7	23
111	Management of Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy: A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2021, 4, 150-169.	5.4	23
112	Efficacy of milk versus water to reduce interfering infra-cardiac activity in 99mTc-sestamibi myocardial perfusion scintigraphy. <i>Nuclear Medicine Communications</i> , 2006, 27, 837-842.	1.1	22
113	Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine Malignancies. <i>PET Clinics</i> , 2015, 10, 461-476.	3.0	21
114	Accuracy and Utility of Deformable Image Registration in 68Ga 4D PET/CT Assessment of Pulmonary Perfusion Changes During and After Lung Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 196-204.	0.8	21
115	PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110538.	3.2	21
116	Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer. <i>Cancers</i> , 2022, 14, 503.	3.7	21
117	68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer. <i>Cancer Imaging</i> , 2017, 17, 31.	2.8	20
118	The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis.. <i>Journal of Nuclear Medicine</i> , 2022, , jnumed.121.263448.	5.0	20
119	Gallium-68 perfusion positron emission tomography/computed tomography to assess pulmonary function in lung cancer patients undergoing surgery. <i>Cancer Imaging</i> , 2016, 16, 24.	2.8	19
120	Bringing clarity or confusion? The role of prostate-specific membrane antigen positron emission/computed tomography for primary staging in prostate cancer. <i>BJU International</i> , 2017, 119, 194-195.	2.5	19
121	Automatic delineation of functional lung volumes with 68Ga-ventilation/perfusion PET/CT. <i>EJNMMI Research</i> , 2017, 7, 82.	2.5	19
122	PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1869-1877.	6.4	19
123	Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapy. <i>Annals of Hematology</i> , 2014, 93, 1193-1200.	1.8	18
124	Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team. <i>BJU International</i> , 2019, 124, 551-553.	2.5	18
125	ENZA trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). <i>BJU International</i> , 2021, 128, 642-651.	2.5	18
126	High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1330-1336.	6.4	17

#	ARTICLE	IF	CITATIONS
127	Modifying the Poor Prognosis Associated with ¹⁸ F-FDG Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT). <i>Journal of Nuclear Medicine</i> , 2015, 56, 968-969.	5.0	17
128	The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer. <i>Current Opinion in Urology</i> , 2019, 29, 569-577.	1.8	17
129	Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 718-727.	6.4	17
130	The utility and limitations of ¹⁸ F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature review. <i>Leukemia and Lymphoma</i> , 2015, 56, 49-56.	1.3	16
131	Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. <i>Prostate</i> , 2020, 80, 1273-1296.	2.3	16
132	Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. <i>European Urology Oncology</i> , 2021, 4, 714-730.	5.4	16
133	Radionuclide Therapy in Prostate Cancer: From Standalone to Combination PSMA Theranostics. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1660-1668.	5.0	16
134	Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e200-e205.	1.9	16
135	Radiation Dosimetry in ¹⁷⁷ Lu-PSMA-617 Therapy. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 243-254.	4.6	16
136	Imaging in follicular NHL. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 165-177.	1.7	15
137	Independent and incremental value of ventilation/perfusion PET/CT and CT pulmonary angiography for pulmonary embolism diagnosis: results of the PECAN pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1596-1604.	6.4	15
138	Single-arm prospective interventional study assessing feasibility of using gallium-68 ventilation and perfusion PET/CT to avoid functional lung in patients with stage III non-small cell lung cancer. <i>BMJ Open</i> , 2020, 10, e042465.	1.9	15
139	Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response” <i>AJR</i> Expert Panel Narrative Review. <i>American Journal of Roentgenology</i> , 2022, 218, 767-780.	2.2	15
140	PRINCE: Phase I trial of ¹⁷⁷ Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 5017-5017.	1.6	15
141	EORTC PET response criteria are more influenced by reconstruction inconsistencies than PERCIST but both benefit from the EARL harmonization program. <i>EJNMMI Physics</i> , 2017, 4, 17.	2.7	14
142	Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option. <i>BJU International</i> , 2020, 126, 525-535.	2.5	14
143	Correlation between percutaneous biopsy and final histopathology for retroperitoneal sarcoma: a single-centre study. <i>ANZ Journal of Surgery</i> , 2020, 90, 497-502.	0.7	14
144	Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer. <i>Future Oncology</i> , 2021, 17, 2225-2241.	2.4	14

#	ARTICLE	IF	CITATIONS
145	A First-in-Human Study of ⁶⁸ Ga-Nanocolloid PET/CT Sentinel Lymph Node Imaging in Prostate Cancer Demonstrates Aberrant Lymphatic Drainage Pathways. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1837-1842.	5.0	13
146	Use of prostate-specific membrane antigen positron emission tomography/CT in response assessment following upfront chemohormonal therapy in metastatic prostate cancer. <i>BJU International</i> , 2020, 126, 433-435.	2.5	13
147	Meningeal recurrence of intravascular large B-cell lymphoma: early diagnosis with PET-CT. <i>British Journal of Haematology</i> , 2007, 137, 386-386.	2.5	12
148	Observer variation in FDG PET-CT for staging of non-small-cell lung carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 194-199.	6.4	12
149	Radiotherapy of abdomen with precise renal assessment with SPECT/CT imaging (RAPRASI): design and methodology of a prospective trial to improve the understanding of kidney radiation dose response. <i>BMC Cancer</i> , 2013, 13, 381.	2.6	12
150	Protracted hypocalcaemia following a single dose of denosumab in humoral hypercalcaemia of malignancy due to PTHrP-secreting neuroendocrine tumour. <i>Clinical Endocrinology</i> , 2014, 81, 940-942.	2.4	12
151	PSMA-PET for Lymph Node Detection in Recurrent Prostate Cancer: How do we use the Magic Bullet?. <i>Theranostics</i> , 2017, 7, 2046-2047.	10.0	12
152	Oligometastatic Renal Cell Carcinoma With Sarcomatoid Differentiation Demonstrating Variable Imaging Phenotypes on ⁶⁸ Ga-PSMA and ¹⁸ F-FDG PET/CT: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 1-5.	1.9	12
153	^{NaF} PET/CT for response assessment of prostate cancer bone metastases treated with single fraction stereotactic ablative body radiotherapy. <i>Radiation Oncology</i> , 2019, 14, 164.	2.7	12
154	Early Outcomes of Surgery for Carcinoid Heart Disease. <i>Heart Lung and Circulation</i> , 2020, 29, 742-747.	0.4	12
155	Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 366-382.	3.8	12
156	White fat, factitious hyperglycemia, and the role of FDG PET to enhance understanding of adipocyte metabolism. <i>EJNMMI Research</i> , 2011, 1, 2.	2.5	11
157	Enhanced White Adipose Tissue Metabolism in Iatrogenic Cushing's Syndrome With FDG PET/CT. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3041-3042.	3.6	11
158	Mechanistic Insights for Optimizing PSMA Radioligand Therapy. <i>Clinical Cancer Research</i> , 2020, 26, 2774-2776.	7.0	11
159	[¹⁷⁷ Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer – Author's reply. <i>Lancet Oncology</i> , The, 2018, 19, e373.	10.7	10
160	Abscopal Regressions of Lymphoma After Involved-Site Radiation Therapy Confirmed by Positron Emission Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 204-211.	0.8	10
161	High prostate-specific membrane antigen (^{PSMA}) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer. <i>BJU International</i> , 2022, 130, 5-7.	2.5	10
162	Where to Next for Theranostics in Prostate Cancer?. <i>European Urology Oncology</i> , 2019, 2, 163-165.	5.4	9

#	ARTICLE	IF	CITATIONS
181	A Novel Application of [18F]Fluorothymidine-PET ([18F]FLT-PET) in Clinical Practice to Quantify Regional Bone Marrow Function in a Patient With Treatment-Induced Cytopenias and to Guide α -Marrow-Sparing Radiotherapy. <i>Clinical Nuclear Medicine</i> , 2019, 44, e624-e626.	1.3	6
182	TheraP: A randomized phase II trial of [¹⁷⁷ Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS332-TPS332.	1.6	6
183	Prostate-specific membrane antigen positron emission tomography/computed tomography funding grants free access to superior staging for Australian men with prostate cancer. <i>BJU International</i> , 2022, 130, 8-10.	2.5	6
184	Not-So-Random Errors: Randomized Controlled Trials Are Not the Only Evidence of the Value of PET. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1820-1822.	5.0	5
185	Fluorodeoxyglucose positron emission tomography/computed tomography for evaluation of bone marrow involvement in lymphoma: when is it superior to biopsy?. <i>Leukemia and Lymphoma</i> , 2012, 53, 349-351.	1.3	5
186	Evaluation of a new visual uptake scoring scale for 18F-fluorothymidine positron emission tomography in the diagnosis of pulmonary lesions. <i>Nuclear Medicine Communications</i> , 2013, 34, 521-526.	1.1	5
187	Thyroid nodules: time to stop over-reporting normal findings and update consensus guidelines. <i>BMJ, The</i> , 2013, 347, f5742-f5742.	6.0	5
188	Prostate-specific membrane antigen from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer. <i>BJU International</i> , 2017, 120, 310-312.	2.5	5
189	Utility of Biology-Guided Radiotherapy to De Novo Metastases Diagnosed During Staging of High-Risk Biopsy-Proven Prostate Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 854589.	2.8	5
190	PSMA PET tumor-to-salivary glands ratio (PSG score) to predict response to Lu-177 PSMA radioligand therapy: An international multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5043-5043.	1.6	5
191	Breast lymphatic drainage via the pulmonary lymphatic system. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 2203-2203.	6.4	4
192	Not-So-Random Errors: Randomized Controlled Trials Are Not the Only Evidence of the Value of PET Rebuttal. <i>Journal of Nuclear Medicine</i> , 2013, 54, 492-492.	5.0	4
193	Let's Get SEERious: More Accurate Staging With Consequent High Management Impact Is Not Just Stage Migration. <i>Journal of Clinical Oncology</i> , 2013, 31, 819-819.	1.6	4
194	Current status of FDG-PET/CT in staging of adult lymphoma. <i>Clinical and Translational Imaging</i> , 2015, 3, 253-269.	2.1	4
195	Role of PET/CT in multimodality imaging in differentiating cardiac sarcoidosis from arrhythmogenic right ventricular dysplasia. <i>Journal of Nuclear Cardiology</i> , 2019, 26, 1761-1765.	2.1	4
196	What is the best PET target for early biochemical recurrence of prostate cancer? Authors' reply. <i>Lancet Oncology, The</i> , 2019, 20, e609-e610.	10.7	4
197	Automated assessment of functional lung imaging with 68Ga-ventilation/perfusion PET/CT using iterative histogram analysis. <i>EJNMMI Physics</i> , 2021, 8, 23.	2.7	4
198	Advanced prostate cancer experimental radioactive treatment clinical trial decision making: patient experiences. <i>BMJ Supportive and Palliative Care</i> , 2021, , bmjspcare-2021-002994.	1.6	4

#	ARTICLE	IF	CITATIONS
199	Segmental Hyperperfusion in Lobar Pneumonia Visualized with Respiratory-gated Four-Dimensional Pulmonary Perfusion Positron Emission Tomographyâ€“Computed Tomography. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 104-105.	5.6	4
200	The Australasian Radiopharmaceutical Trials Network: Clinical Trials, Evidence, and Opportunity. Journal of Nuclear Medicine, 2021, 62, 755-756.	5.0	4
201	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 6-11.	1.9	4
202	A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapse. Leukemia and Lymphoma, 2022, 63, 1-4.	1.3	4
203	Quantitative assessment of ventilation-perfusion relationships with gallium-68 positron emission tomography/computed tomography imaging in lung cancer patients. Physics and Imaging in Radiation Oncology, 2022, 22, 8-12.	2.9	4
204	How do we best balance optimal timing of FDG PETâ€“CT imaging?. Nuclear Medicine Communications, 2007, 28, 885-887.	1.1	3
205	Evaluating the place of 18-fluoro-2-deoxy-d-glucose positron emission tomography scanning in primary staging and beyond in patients with follicular lymphoma. Leukemia and Lymphoma, 2013, 54, 2093-2095.	1.3	3
206	Early warning signs: FDG-PET to diagnose bleomycin toxicity. Leukemia and Lymphoma, 2017, 58, 1016-1018.	1.3	3
207	ProPSMA: A Callout to the Nuclear Medicine Community to Change Practices with Prospective, High-Quality Data. Journal of Nuclear Medicine, 2020, 61, 676-677.	5.0	3
208	TU-A-WAB-08: Strong Evidence for Physiologic Correlation of 4D-CT Ventilation Imaging with Respiratory-Related Gallium 68 PET/CT in Humans. Medical Physics, 2013, 40, 424-424.	3.0	3
209	Prostate-Specific Membrane Antigen: The Target of the Decade, from Biochemical Recurrence to Widespread Adoption (perspective on â€œEvaluation of hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients) Tj ETQq1 1 0.784314 rgBT (C) Nuclear Medicine, 2020, 61, 246S-254S.	5.0	3
210	Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour. Clinical and Translational Radiation Oncology, 2022, 35, 84-89.	1.7	3
211	False-Negative Myocardial Perfusion Scintigraphy Possibly as a Result of Administration of Low-Molecular-Weight Heparin. Clinical Nuclear Medicine, 2007, 32, 70-72.	1.3	2
212	Using positron emission tomography to assess tumor proliferation in non-Hodgkin lymphoma. Leukemia and Lymphoma, 2010, 51, 183-185.	1.3	2
213	Fluorodeoxyglucose positron emission tomography/computed tomography: a "one stop shop" for diagnosing polymyalgia rheumatica. BMJ, The, 2014, 348, f7705-f7705.	6.0	2
214	Short and long-term prognostic implications of a low embolic burden in oncology patients diagnosed with symptomatic pulmonary embolism. Annals of Hematology, 2016, 95, 651-652.	1.8	2
215	Intense focal pituitary FDG uptake due to intravascular large Bâ€œcell lymphoma in pyrexia of unknown origin. American Journal of Hematology, 2016, 91, 1167-1168.	4.1	2
216	â€“Hot spotâ€™ cardiac ischemia imaging with fluorodeoxyglucose positron emission tomography. Journal of Nuclear Cardiology, 2016, 23, 1514-1517.	2.1	2

#	ARTICLE	IF	CITATIONS
217	Principles and Application of Molecular Imaging for Personalized Medicine and Guiding Interventions in Neuroendocrine Tumors. , 2017, , 219-238.		2
218	Reply to Fabio Zattoni, Filiberto Zattoni, and Laura Evangelista's Letter to the Editor re: Marlon Perera, Nathan Papa, Daniel Christidis, et al. Sensitivity, Specificity, and Predictors of Positive 68 Gaâ€“Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol 2016;70:926â€“37. European Urology, 2017, 71, e66-e67.	1.9	2
219	The evolving definition of bulky disease for lymphoma. Leukemia and Lymphoma, 2020, 61, 1525-1528.	1.3	2
220	Intra-patient comparison of physiologic 68Ga-PSMA-11 and 18F-DCFPyL PET/CT uptake in ganglia in prostate cancer patients: a pictorial essay. Cancer Imaging, 2021, 21, 35.	2.8	2
221	Bringing VISION to Nuclear Medicine: accelerating evidence and changing paradigms with theranostics. Journal of Nuclear Medicine, 2021, , jnumed.121.262890.	5.0	2
222	Unintended consequences: might major surgery accelerate cancer?. BMJ, The, 2014, 348, g247-g247.	6.0	1
223	Re: Palliative bypass for small bowel carcinoid with mesenteric mass and vascular encasement. ANZ Journal of Surgery, 2015, 85, 197-197.	0.7	1
224	FDG PET in follicular lymphoma: more than a staging test?. Leukemia and Lymphoma, 2017, 58, 1521-1523.	1.3	1
225	Using PSMA PET/CT to assess response in metastatic prostate cancer (mPC) patients (pts) receiving upfront chemohormonal therapy. Annals of Oncology, 2018, 29, ix70-ix71.	1.2	1
226	A pilot study of cardiopulmonary exercise testing and cardiac stress positron emission tomography before major nonâ€œcardiac surgery. Anaesthesia, 2018, 73, 1524-1530.	3.8	1
227	A Self-Fulfilling Prophecy: Comparing ¹⁷⁷Lu-PSMA Radioligand Therapy in Taxane-NaÃ“ve Versus Posttaxane Metastasized Prostate Cancer Patients?. Journal of Nuclear Medicine, 2019, 60, 1494-1494.	5.0	1
228	Nodal metabolic tumour volume on baseline 18 Fâ€“FDG PET/CT and overall survival in stage II and III NSCLC patients undergoing curativeâ€œintent chemoradiotherapy/radiotherapy. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 748-754.	1.8	1
229	The Global Reading Room: Nuclear Medicine Imaging of Suspected Paraganglioma. American Journal of Roentgenology, 2021, 217, 1008-1009.	2.2	1
230	Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial.. Journal of Clinical Oncology, 2018, 36, 5040-5040.	1.6	1
231	The â€œProPSMA Studyâ€œclinical trial protocol: A prospective randomized multi-center study of the impact of Ga-68 PSMA PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy.. Journal of Clinical Oncology, 2019, 37, TPS138-TPS138.	1.6	1
232	Outcomes of peptide receptor radionuclide therapy (PRRT) in metastatic grade 3 neuroendocrine tumors (NETs).. Journal of Clinical Oncology, 2017, 35, e15694-e15694.	1.6	1
233	The poor outcome of patients with mCRPC whom were deemed ineligible for PSMA theranostics based on molecular imaging characteristics.. Journal of Clinical Oncology, 2018, 36, e17002-e17002.	1.6	1
234	Impact of Post-Transplant Consolidative Radiotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma and a PET-CT Based Predictive Model for Relapse. Blood, 2019, 134, 4044-4044.	1.4	1

#	ARTICLE	IF	CITATIONS
235	Circulating tumour cells (CTCs) and PSMA PET correlates in the phase I PRINCE trial of ¹⁷⁷ Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 5027-5027.	1.6	1
236	Special delivery: getting radiation to the target in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2012, 53, 751-753.	1.3	0
237	PET Screening for Metastatic Colorectal Adenocarcinoma. JAMA - Journal of the American Medical Association, 2014, 312, 1255.	7.4	0
238	V4-07 EARLY EXPERIENCE OF ROBOTIC SALVAGE PELVIC LYMPH NODE DISSECTION IN THE GA-68 PSMA PET SCANNING ERA. Journal of Urology, 2016, 195, .	0.4	0
239	Prognostic biomarkers in locally advanced cervical cancer (Cx Ca) treated with chemoradiation (CRT). Annals of Oncology, 2016, 27, vi35.	1.2	0
240	Role of PET/CT in Melanoma. , 2017, , 37-51.		0
241	PET/CT in Melanoma (Additional Teaching Cases). , 2017, , 53-63.		0
242	Accuracy in the Eye of the Beholder: Can We Improve Agreement in Prostate Cancer Diagnostics with PSMA PET/CT?. Journal of Nuclear Medicine, 2017, 58, 1615-1616.	5.0	0
243	Tumour Biology Characterisation by Imaging in Clinic. Medical Radiology, 2020, , 325-360.	0.1	0
244	Gallium-68 Ventilation/Perfusion PET-CT and CT Pulmonary Angiography for Pulmonary Embolism Diagnosis: An Interobserver Agreement Study. Frontiers in Medicine, 2020, 7, 599901.	2.6	0
245	Perspectives on Cutting-Edge Clinical Trials. Journal of Nuclear Medicine, 2021, 62, 1027-1030.	5.0	0
246	Targeted radioactive therapy for prostate cancer – Authors' reply. Lancet, The, 2021, 398, 488.	13.7	0
247	Development and Validation of Nomograms to Predict Outcome Following LuPSMA Radionuclide Treatment for Metastatic Castration-Resistant Prostate Cancer: A Multicenter International Study. SSRN Electronic Journal, 0, , .	0.4	0
248	Breast Cancer: Role of Planar, SPECT and PET in Imaging Bone Metastases. , 2012, , 661-689.		0
249	Lack Of Benefit From Surveillance PET-CT In Transformed Indolent Lymphoma (TrIL) In Complete Metabolic Remission (CMR) Following Therapy. Blood, 2013, 122, 1796-1796.	1.4	0
250	Patterns of failure on Ga PSMA (GaPSMA) and F18 FDG (FDG) PET CT in a prospective phase 2 trial of ¹⁷⁷ Lu DKFZ PSMA 617 (LuPSMA) in men with castrate resistant metastatic prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 2562-2562.	1.6	0
251	AGITG nabnec: A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas.. Journal of Clinical Oncology, 2018, 36, TPS548-TPS548.	1.6	0
252	Prospective head-to-head comparative phase 3 study between ¹⁸ F-fluciclovine and ⁶⁸ Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer.. Journal of Clinical Oncology, 2019, 37, 5014-5014.	1.6	0

#	ARTICLE	IF	CITATIONS
253	Correlation of positron emission tomography ventilation-perfusion matching with CT densitometry in severe emphysema. EJNMMI Research, 2020, 10, 86.	2.5	0
254	Editorial Comment. Journal of Urology, 2020, 203, 99-99.	0.4	0
255	Evaluating the PET Parameters SUVmax and TMTV in the Setting of Autologous Stem Cell Transplantation for DLBCL. Blood, 2020, 136, 38-38.	1.4	0
256	PET imaging of prostate cancer. , 2022, , .		0